ENDYMED Merges with Majority Shareholder Shanghai Haohai Biological Technology

The9 Limited’s Investee Nanyang Biologics Advances Planned Nasdaq Listing in US$1.5 Billion Business Combination

August 11, 2026

AI & Machine Learning

The9 Limited said its Singapore investee Nanyang Biologics Pte. Ltd. (NYB) received notice of effectiveness from the U.S. SEC for its Form F-4 registration statement tied to a previously announced business combination valued at about US$1.5 billion. The listing is planned on Nasdaq (ticker symbol “NYB”), subject to NYB’s SPAC extraordinary general meeting and Nasdaq approval.

LianMedical Completes Merger Between LianBio and LianMedical

July 17, 2026

Medical Devices

LianMedical (formerly LianBio) announced the completion of its previously announced merger between LianBio and LianMedical. Under the approved plan of merger, LianMedical merged with and into LianBio, and LianBio continued as the surviving company, with the company changing its name to LianMedical effective upon completion.

L&C Bio (L&C Bio Co., Ltd) Completes Acquisition of L&C China for MegaDerm Plus NMPA Approval

January 22, 2025

Medical Devices

L&C Bio announced it has received China’s NMPA approval for its acellular dermal matrix “MegaDerm Plus,” intended to begin full-scale sales in the first half of 2025. Separately, the company said it is completing the acquisition of 100% ownership of L&C China using its own funds, without issuing convertible bonds, to make L&C China a wholly owned subsidiary and to control its China operations.

EmergentMedTech Merges with TRU Biologix

January 22, 2025

Biotechnology

EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.

INVO Bioscience Acquires NAYA Biosciences in All-Stock Merger

October 14, 2024

Healthcare Services

INVO Bioscience and NAYA Biosciences entered into a definitive all-stock merger agreement under which INVO would acquire 100% of NAYA in a reverse triangular merger. The combined company operates as NAYA Biosciences and trades on NASDAQ under the “NAYA” ticker after closing.

Montagu Acquires Majority Stake in HTL Biotechnology

February 28, 2022

Pharmaceuticals

Montagu, a leading private equity firm, has acquired a majority stake in HTL (HTL Biotechnology) from Bridgepoint, with minority shareholders Naxicap and Téthys Invest retaining their holdings. Montagu will support HTL's international expansion, R&D and premium product positioning and has appointed Paul Navarre as Chairman to help drive the company's next growth phase.